The Rise of Antibiotic Resistance Industry

Antibiotics have been used for the past 70 years to treat bacterial infections. However, as antibiotic use increases worldwide, more and more bacteria are developing resistance to the drugs designed to kill them. Antibiotic resistance occurs when bacteria change in ways that reduce the effectiveness of drugs, necessitating the need for stronger antibiotics. Unfortunately, bacteria are very adept at becoming resistant, and they can pass resistance genes to other bacteria, creating "superbugs." Overuse and misuse of antibiotics are accelerating this natural process, resulting in many infections that no longer respond to treatment.

Overprescription of Antibiotic Resistance Industry

According to the Centers for Disease Control and Prevention, up to 50% of all the antibiotics prescribed for people are not needed or are not optimally effective as prescribed. The overuse of antibiotics in human medicine provides continuous selective pressure that drives the emergence and spread of resistance. Prescribers sometimes feel compelled to prescribe antibiotics for respiratory infections that are often caused by viruses and will not respond to such drugs. While patients often demand antibiotics from their doctors, they may continue to experience symptoms even when using them. Healthcare providers must improve prescribing practices through clinical decision support and audit and feedback to reduce unnecessary use.

Indiscriminate Use in Agriculture

Global Antibiotic Resistance are also widely used in livestock production for disease prevention and growth promotion purposes rather than treatment of sick animals. It is estimated that over 70% of all medically important antibiotics in the U.S. are sold for use in livestock. This overuse contributes to the emergence of antibiotic-resistant bacteria through continuous low-level exposure. While some countries have restricted or banned specific non-medical uses in food animal production to curb resistance, the practice continues in many regions. Alternatives need to be adopted to reduce reliance on antibiotics for growth promotion and disease prevention in healthy food animals.

Limited Pipeline of New Drugs

With the growing threat of resistance, new antibiotic drugs are urgently needed. However, pharmaceutical companies have lost interest in developing novel classes of antibiotics due to low profitability compared to drugs for chronic illnesses. The antibiotic discovery pipeline is drying up precisely when new therapies are most needed. Reforms are being explored to incentivize pharmaceutical investment in antimicrobial drug R&D through market entry rewards, increased public-private partnerships, and new models like the global antibiotic research and development facility. Sustainable funding streams beyond traditional mechanisms are necessary to tackle this critical public health challenge.

Spread of Resistance Globally

Antibiotic-resistant bacteria recognize no geographic boundaries. In our interconnected world, resistant pathogens can spread between countries and continents aided by international travel and trade. Even regions with prudent antibiotic stewardship programs are affected by importing resistant strains from other parts of the world. Resistance also spreads to the community setting from healthcare facilities when patients acquire infections from resistant bacteria and return home. Strengthening global surveillance networks and developing international guidelines are important strategies to coordinate efforts against this emerging borderless threat.

Solutions Require Coordinated Action

Addressing antibiotic resistance demands a coordinated "One Health" approach that connects human medicine, veterinary medicine, and the environment. Multiple sectors must work together to optimize antibiotic use in humans and animals, develop economic incentives for drug R&D, improve infection prevention, and expand global surveillance and response networks. National action plans with targets, monitoring and accountability are being adopted by many countries.

While the problem took decades to develop, stemming the rise of superbugs will require sustained multifaceted efforts from governments, health professionals, agricultural industries and citizens across the world. With prudent stewardship of existing antibiotics and a renewed investment in novel therapies, antibiotic resistance can be slowed, though the challenges ahead remain immense.

Get more insights on Global Antibiotic Resistance